Figure 5.

The effect of signature-signature and signature-pathway interactions on patient survival

(A and B) Summary of survival effect of age at diagnosis and tumor mutational burden (TMB) across samples in TCGA and PCAWG. The letters to the left indicate the dataset. The error bars in A,B, C, D, F correspond to the 95% confidence interval of the HR estimate.

(C and D) The log hazard ratio of signature-signature interactions with a significant effect on survival in PCAWG and TCGA.

(E) Survival curves of pancreatic, prostate, ovarian adenocarcinomas, and medulloblastoma with SBS40 signature, ROS signature (SBS18), a combination, or none, adjusted for age at diagnosis, cancer type, and log-transformed tumor mutational burden.

(F) The log hazard ratio of signature-pathway interactions with a significant effect on survival in TCGA. See also Figure S5.